

# Behdad Afzali

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8602236/publications.pdf>

Version: 2024-02-01

85  
papers

5,870  
citations

76326

40  
h-index

76900

74  
g-index

119  
all docs

119  
docs citations

119  
times ranked

8673  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. <i>Nature Immunology</i> , 2022, 23, 62-74.	14.5	105
2	The state of complement in COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 77-84.	22.7	159
3	Aberrant type 1 immunity drives susceptibility to mucosal fungal infections. <i>Science</i> , 2021, 371, .	12.6	84
4	BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. <i>Nature Immunology</i> , 2021, 22, 370-380.	14.5	75
5	MicroRNA-221 and -222 modulate intestinal inflammatory Th17 cell response as negative feedback regulators downstream of interleukin-23. <i>Immunity</i> , 2021, 54, 514-525.e6.	14.3	30
6	SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. <i>Science Immunology</i> , 2021, 6, .	11.9	144
7	Fibroblast tissue priming“ not so nice to C you!. <i>Immunity</i> , 2021, 54, 847-850.	14.3	4
8	Host-Virus Chimeric Events in SARS-CoV-2-Infected Cells Are Infrequent and Artifactual. <i>Journal of Virology</i> , 2021, 95, e0029421.	3.4	28
9	Response to Comments on “Aberrant type 1 immunity drives susceptibility to mucosal fungal infections” <i>Science</i> , 2021, 373, eabi8835.	12.6	5
10	Reply to Grigoriev et al., “Sequences of SARS-CoV-2 “Hybrids” with the Human Genome: Signs 1 of Non-coding RNA?” <i>Journal of Virology</i> , 2021, , JVI0169021.	3.4	0
11	Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics. <i>Advances in Immunology</i> , 2021, 152, 1-81.	2.2	7
12	Mitochondrial C5aR1 activity in macrophages controls IL-1 $\beta$ production underlying sterile inflammation. <i>Science Immunology</i> , 2021, 6, eabf2489.	11.9	50
13	Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. <i>Gut</i> , 2020, 69, 578-590.	12.1	84
14	Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells. <i>Journal of Virology</i> , 2020, 94, .	3.4	26
15	Diapedesis-Induced Integrin Signaling via LFA-1 Facilitates Tissue Immunity by Inducing Intrinsic Complement C3 Expression in Immune Cells. <i>Immunity</i> , 2020, 52, 513-527.e8.	14.3	57
16	Integrated Pan-Cancer Map of EBV-Associated Neoplasms Reveals Functional Host“Virus Interactions. <i>Cancer Research</i> , 2019, 79, 6010-6023.	0.9	43
17	STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells. <i>Journal of Immunology</i> , 2018, 200, 110-118.	0.8	29
18	Human retinoic acid“regulated CD161+ regulatory T cells support wound repair in intestinal mucosa. <i>Nature Immunology</i> , 2018, 19, 1403-1414.	14.5	86

#	ARTICLE	IF	CITATIONS
19	Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. <i>Nature Communications</i> , 2018, 9, 4186.	12.8	75
20	Unexpected Roles for Intracellular Complement in the Regulation of Th1 Responses. <i>Advances in Immunology</i> , 2018, 138, 35-70.	2.2	20
21	BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. <i>Nature Immunology</i> , 2017, 18, 813-823.	14.5	113
22	Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. <i>JCI Insight</i> , 2017, 2, e87379.	5.0	28
23	The C3-like molecule CD109 controls Th1 versus Th17 induction in CD4+ T cells. <i>Immunobiology</i> , 2016, 221, 1195-1196.	1.9	0
24	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 <sup>+</sup> T cells. <i>Science</i> , 2016, 352, aad1210.	12.6	395
25	Developing in vitro expanded CD45RA <sup>+</sup> regulatory T cells as an adoptive cell therapy for Crohn's disease. <i>Gut</i> , 2016, 65, 584-594.	12.1	163
26	Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. <i>Haematologica</i> , 2016, 101, 91-100.	3.5	64
27	Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions. <i>ELife</i> , 2016, 5, .	6.0	74
28	EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion. <i>Scientific Reports</i> , 2015, 5, 10643.	3.3	129
29	Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses. <i>Immunity</i> , 2015, 42, 1033-1047.	14.3	190
30	Regulatory T-Cell Therapy in the Induction of Transplant Tolerance. <i>Transplantation</i> , 2014, 98, 370-379.	1.0	70
31	Vitamin D in Renal Transplantation – from Biological Mechanisms to Clinical Benefits. <i>American Journal of Transplantation</i> , 2014, 14, 1259-1270.	4.7	44
32	CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. <i>European Journal of Immunology</i> , 2013, 43, 2043-2054.	2.9	114
33	Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation. <i>Immunity</i> , 2013, 39, 1143-1157.	14.3	444
34	Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 5-7.	3.1	4
35	Comparison of Regulatory T Cells in Hemodialysis Patients and Healthy Controls. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1396-1405.	4.5	77
36	Regulatory T cells in renal cell carcinoma: additional fuel to the bonfire of debate. <i>BJU International</i> , 2013, 112, 538-539.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations. <i>Haematologica</i> , 2013, 98, 1291-1299.	3.5	127
38	Thymic Versus Induced Regulatory T Cells – Who Regulates the Regulators?. <i>Frontiers in Immunology</i> , 2013, 4, 169.	4.8	74
39	<i>Helicobacter pylori</i> induces in vivo expansion of human regulatory T cells through stimulating interleukin-1 <sup>2</sup> production by dendritic cells. <i>Clinical and Experimental Immunology</i> , 2012, 170, 300-309.	2.6	23
40	Core Concepts in Renal Transplantation Edited by Anil Chandraker Mohamed H Sayegh Ajay K Singh Springer 2012 £126.00. 242 978 1 4614 0007 3. British Journal of Hospital Medicine (London, England:) Tj ETQq0050 rgBT0Overlock		
41	A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. <i>Blood</i> , 2012, 119, e57-e66.	1.4	74
42	Relative Resistance of Human CD4+ Memory T Cells to Suppression by CD4+CD25+ Regulatory T Cells. <i>American Journal of Transplantation</i> , 2011, 11, 1734-1742.	4.7	34
43	Cell therapy to promote transplantation tolerance: a winning strategy?. <i>Immunotherapy</i> , 2011, 3, 28-31.	2.0	17
44	IL-2 Regulates Expression of C-MAF in Human CD4 T Cells. <i>Journal of Immunology</i> , 2011, 187, 3721-3729.	0.8	29
45	T-cell alloimmunity and chronic allograft dysfunction. <i>Kidney International</i> , 2010, 78, S2-S12.	5.2	53
46	Anti-TNF± therapy – killing two birds with one stone?. <i>Lancet, The</i> , 2010, 375, 2278.	13.7	10
47	T.10.5. Subversion of Human CD4+CD25+Regulatory T Cells to IL-17-Producing T Cells by Pathogen-induced Inflammatory Milieu. <i>Clinical Immunology</i> , 2009, 131, S50.	3.2	0
48	IL-17-producing CD4 <sup>+</sup> T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2009, 145, 64-72.	2.5	169
49	The T helper 17 – regulatory T cell axis in transplant rejection and tolerance. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 326-331.	1.6	81
50	Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. <i>Haematologica</i> , 2009, 94, 956-966.	3.5	32
51	Relative roles of Th1 and Th17 effector cells in allograft rejection. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 23-29.	1.6	59
52	Translational Mini-Review Series on Th17 Cells: Induction of interleukin-17 production by regulatory T cells. <i>Clinical and Experimental Immunology</i> , 2009, 159, 120-130.	2.6	124
53	Pathways of major histocompatibility complex allorecognition. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 438-444.	1.6	125
54	Increased Number of IL-17 Producing CD4+ T Cells in Low Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2008, 112, 637-637.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The maintenance of human CD4+CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. <i>International Immunology</i> , 2007, 19, 785-799.	4.0	89
56	CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). <i>Blood</i> , 2007, 110, 847-850.	1.4	234
57	Falls, hypokalaemia, and a dry mouth. <i>Lancet, The</i> , 2007, 370, 192.	13.7	4
58	Long-term risks of increased use of intravenous iron. <i>Lancet, The</i> , 2007, 370, 482.	13.7	1
59	Allorecognition and the alloresponse: clinical implications. <i>Tissue Antigens</i> , 2007, 69, 545-556.	1.0	142
60	The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. <i>Clinical and Experimental Immunology</i> , 2007, 148, 32-46.	2.6	632
61	Diabetes, kidney disease and anaemia: time to tackle a troublesome triad?. <i>International Journal of Clinical Practice</i> , 2007, 61, 281-289.	1.7	20
62	Intercellular Transfer of MHC and Immunological Molecules: Molecular Mechanisms and Biological Significance. <i>American Journal of Transplantation</i> , 2007, 7, 1442-1449.	4.7	67
63	Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors. <i>Transplantation</i> , 2006, 81, 1112-1118.	1.0	104
64	Anaemia in diabetic patients with chronic kidney disease—prevalence and predictors. <i>Diabetologia</i> , 2006, 49, 1183-1189.	6.3	59
65	Transmission of Syphilis by Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2006, 6, 2497-2499.	4.7	39
66	Anemia After Renal Transplantation. <i>American Journal of Kidney Diseases</i> , 2006, 48, 519-536.	1.9	72
67	Post-transplantation anaemia in adult and paediatric renal allograft recipients—Guy's Hospital experience. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1974-1980.	0.7	25
68	Compromise of renal transplant blood flow by an arteriovenous graft. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2644-2646.	0.7	2
69	Bleeding post coronary artery bypass surgery. Clopidogrel—cure or culprit?. <i>Journal Medical Libanais</i> , 2006, 54, 11-6.	0.0	6
70	Low-Dose Mycophenolate Mofetil is an Effective and Safe Treatment to Permit Phased Reduction in Calcineurin Inhibitors in Chronic Allograft Nephropathy. <i>Transplantation</i> , 2005, 79, 304-309.	1.0	27
71	What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations. <i>Kidney International</i> , 2005, 68, 2429-2443.	5.2	23
72	Commentary: Microalbuminuria—the next target for vascular disease prevention?. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 342-343.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Embryo and Fetal Pathology. Color Atlas with Ultrasound Correlation. Journal of Clinical Pathology, 2005, 58, 784-784.	2.0	1
74	Treatment of unilateral obstruction reversing heavy and bilateral proteinuria. Nephrology Dialysis Transplantation, 2005, 20, 210-212.	0.7	8
75	Measuring Blood Pressure in Stable Renal Transplant Recipients: What You Measure Depends on What You Use. Nephron Clinical Practice, 2004, 97, c98-c102.	2.3	0
76	From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 2161-2168.	6.1	24
77	Beneficial effects of statins on the kidney: the evidence moves from mouse to man. Nephrology Dialysis Transplantation, 2004, 19, 1032-1036.	0.7	16
78	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clinical Transplantation, 2004, 18, 201-204.	1.6	26
79	Cardiac calcification in renal patients: what we do and don't know. American Journal of Kidney Diseases, 2004, 43, 234-243.	1.9	72
80	Intravenous iron therapy in renal failure: friend and foe?. Journal of Nephrology, 2004, 17, 487-95.	2.0	21
81	Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome. Clinical Nephrology, 2003, 59, 225-228.	0.7	2
82	Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. Journal of Nephrology, 2003, 16, 540-5.	2.0	20
83	Differential expression of $\hat{I}^2$ 1 and $\hat{I}^2$ 2 integrins and L-selectin on CD4+ and CD8+ T lymphocytes in human blood: comparative analysis between isolated cells, whole blood samples and cryopreserved preparations. Clinical and Experimental Immunology, 2002, 127, 60-65.	2.6	22
84	Haematogenous Cell Responses to CNS Injury. , 1998, , 61-78.		0
85	Infections in Hemodialysis. , 0, , 441-451.		1